Sangamo Therapeutics Seeks Regulatory Approval for Fabry Disease Gene Therapy
Published on 02/22/2026 at 07:00 | Editorial boerse-global.de
Sangamo Therapeutics has announced a series of strategic moves, including detailed clinical trial data and the initiation of a regulatory submission for its Fabry disease gene therapy candidate. The company is also bolstering its balance sheet through a new capital raise and has made a change in its financial leadership. These developments aim to strengthen investor confidence in the biotech firm’s long-term financial pathway.
Concurrent with its clinical progress, Sangamo is reinforcing its financial position. The company has launched a public offering of common stock and warrants, which is expected to generate gross proceeds of approximately $25 million. Management has indicated these funds are designated for general corporate working capital purposes.
This Read more...
